Lv3
290 积分 2021-03-11 加入
A tale of two antibodies: obinutuzumab versus rituximab
9小时前
待确认
Targeting B Cells and Plasma Cells in Glomerular Disease
16天前
已完结
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
17天前
已完结
Obinutuzumab is effective for the treatment of frequently-relapsing/steroid-dependent minimal change disease in adults
1个月前
已完结
B cell dysregulation and depletion therapy in primary membranous nephropathy: Prospects and potential challenges
1个月前
已完结
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
1个月前
已完结
Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy
1个月前
已完结
Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy
1个月前
已完结
Effects of different B-cell-depleting strategies on the lymphatic tissue
2个月前
已完结
POS0230 DISAGREEMENT BETWEEN PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OVER TIME IN PSORIATIC ARTHRITIS: INSIGHT INTO TREATMENT PRIORITIES
3个月前
已完结
皖公网安备34019202002308
